Physician profile
Sai Ramakrishna Velamuri Venkata
NPI 1962631341
$302,986.17
in general payments reported to CMS, 2019-2025
26 companies · $26K in 2025
The $26K reported for 2025 was more than what 98% of Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $10K · 2021: $16K · 2022: $56K · 2023: $98K · 2024: $55K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $111K · Travel and Lodging: $26K · Consulting Fee: $19K · Food and Beverage: $7,511 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,275 · Education: $6,000 · Honoraria: $2,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $111,389.89 |
| Travel and Lodging | $25,719.70 |
| Consulting Fee | $18,800.00 |
| Food and Beverage | $7,511.36 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,275.00 |
| Education | $6,000.00 |
| Honoraria | $2,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $168,532.26 | 2019-2025 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Medline Industries Lp | $101,587.43 | 2019-2022 | |
| Polynovo North America LLC | $11,105.96 | 2024-2025 | Novosorb Btm |
| Polymedics Innovations INC. | $7,087.07 | 2022-2024 | |
| Ovik Health, LLC | $6,582.00 | 2019-2023 | |
| Polarityte, INC. | $5,694.03 | 2019 | |
| Organogenesis INC. | $833.84 | 2021-2023 | Apligraf, Puraply Antimicrobial, Nushield |
| Avita Medical Americas, LLC | $392.57 | 2019-2025 | Cohealyx, Recell, Permeaderm |
| Smith+Nephew, INC. | $209.82 | 2020-2023 | Grafix Pl |
| Abbvie INC. | $165.51 | 2021-2023 | Dalvance, Avycaz, Teflaro |
| Musculoskeletal Transplant Foundation INC. | $146.73 | 2025 | |
| Allergan, INC. | $92.47 | 2019 | |
| Integra Lifesciences Corporation | $65.57 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Masimo Corporation | $62.54 | 2021 | |
| Merck Sharp & Dohme LLC | $61.60 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $52.20 | 2021 | |
| Aroa Biosurgery Incorporated | $47.92 | 2025 | |
| Stryker Corporation | $47.62 | 2019 | |
| Misonix INC | $44.01 | 2019 | |
| Tela Bio, INC. | $42.84 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Reprise Biomedical, INC. | $36.85 | 2021 | |
| Melinta Therapeutics, LLC | $34.33 | 2019 | |
| Trevena, INC. | $22.91 | 2022 | |
| Bioventus LLC | $22.20 | 2020 | |
| Medela LLC | $15.89 | 2021-2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sai Ramakrishna Velamuri Venkata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.